Treatment of Angina: Drugs vs Intervention Fausto J. Pinto, MD, PhD, FESC, FACC Lisbon University, Portugal
Fausto J. Pinto, MD, PhD, FESC, FASE, FACC, FSCAI
Disclosures:
Consultancy, advisory boards and lecture fees:
Astra Zeneca, Bayer, Bial, Boehringher Ingelheim, Covidien, GE, Irokio, Menarini, Pfizer, Servier
fjp
Chronic ischemic heart disease : a changing scenario Increase in general population life expectancy (1 in 3 men and women aged over 65 years have some form of cardiovascular disease including angina) Significant increase in risk factors such as obesity, lipids, smoking diabetes, etc. (incidence of CAD has been shown to rise by as much as 55% among adult diabetic patients) Increase in revascularization procedures (resistant and recurrent angina) Frequent comorbidities (30% of primary care practice CAD patients have an altered cardiac function)
Jackson G. Angina. 4th ed. London, UK: Informa Healthcare; 2008. Management of stable angina pectoris. Recommendations from the Task Force of the ESC. Eur Heart J. 2006;27:1341-1381. K. Kotseva et al. Lancet. 2009;373:929-940. Marso SP and Stern DM. Diabetes and cardiovascular disease. Integrating science and clinical medicine. Philadelphia, PA: Lippincott Williams & Wilkins; 2004. Gibbons RJ, et al. J Am Coll Cardiol. 2003;41:159-168. - Malergue M.C, et al. P470: Prevalence of left ventricular systolic dysfunction in stable coronary artery disease patients. 8th International Congress on Coronary Artery Disease, Prague, Czech Republic, 10/2009.
Clinical patterns of stable coronary artery disease The Heart and Soul study (n=937)
Angina
38%
Exerciseinduced ischemia (by ETT)
38% of outpatients with stable CAD have angina or ischemia or both
Gehi AK, et al. Arch Intern Med. 2008;168:1423-1428.
Many patients continue to experience angina after ACS The MERLIN-TIMI 36 trial (n=5460) Rate of angina reported at 4 months after ACS (%) 60
50
50.2
49.8% of patients reported angina at 4 months after ACS
40 29.5
30 20
15.6
10
4.7
0 No angina
Monthly angina
Arnold SV, et al. Circ Cardiovasc Qual Outcomes. 2009;2:344-353.
Weekly angina
Daily angina
Ischemia or angina or both increase the risk of cardiovascular events The Heart and Soul Study (n=937) Survival rate (%)
100
No angina, no ischemia Angina alone
90
Ischemia alone 80 Angina and ischemia 70
60
50 0
Among patients with CAD, angina confers a 3-fold risk of cardiovascular events versus absence of angina
5
10
Gehi AK, et al. Arch Intern Med. 2008;168:1423-1428.
15
20
25
30
35
40
Months
fjp
Annual event rates in stable CAD outpatients is high Annual event rates in stable CAD outpatients, REACH registry: CAD outpatients (n=38602), 1-year follow-up
1.4
Non-fatal MI
6.44
UA 1.4
CABG PCI
3 of 20 patients with established CAD had a major event or had been hospitalized within a year
3.8 4.9
CHF CV death
1.8
Death/MI/ Stroke/Hosp*
15.2 0
PG Steg, et al. JAMA. 2007;297:1197-1206.
5
10
15
Atherothrombosis reduces life expectancy by around 8-12 years in patients aged over 60 years Average remaining life expectancy at age 60 (men)
Year s
20 18 16 14 12 10 8 6 4 2 0 Healthy
History of CV disease
Peeters, et al. Eur Heart J. 2002;23:458-466. Analysis of data from the Framingham Heart Study.
History of AMI
Acute Coronary Syndrome without CAD (normal coronary angiography) 35 30 25 20 15
Men Women
10 5 0 MI with ST
MI without ST
Unstable angina
Hochman JS, et al GUSTO Iib. N Engl J Med. 1999;341:226-232.
Angina and CAD Observed prevalence
CAD50 Prevalence (%)
100
Expected (Guideline Probabilities)
Men (n=7113, 1619 with CAD50)
80
60 0.5
1.6
0.4
40 0.4
1.1 20 1.3 0
30- 4039 39
5059
60- 70+ 69
Asymptomatic
0.5
30- 4039 39
0.1
0.2
50- 60- 70+ 30- 4059 69 39 39
Nonanginal Chest Pain
0.3
0.3 0.0 5059
60- 70+ 69
Atypical Angina
30- 4039 39
5059
Typical Angina
60- 70+ 69
Age (years)
Chen VY, et al. Circulation. 2011;124:2423-2432.
Angina and CAD Observed prevalence
CAD50 Prevalence (%)
100
Expected (Guideline Probabilities)
Women (n=5684, 716 with CAD50)
80
60 0.2 0.2
40 0.2 20 1.5 0
30- 4039 39
5059
60- 70+ 69
Asymptomatic
1.7
30- 4039 39
1.3
0.9 0.3
0.3
50- 60- 70+ 30- 4059 69 39 39
Nonanginal Chest Pain
0.2 5059
0.2 0.2 60- 70+ 69
Atypical Angina
30- 4039 39
5059
Typical Angina
60- 70+ 69
Age (years)
Chen VY, et al. Circulation. 2011;124:2423-2432.
Angina and CAD: an elusive link! 1. Most patients with typical angina do not have coronary atherosclerotic obstructions 2. Prevalence of coronary atherosclerotic obstruction in patients with typical angina and without is similar 3. Female patients have a lower prevalence of coronary atherosclerotic obstruction than male patients 4. Prevalence of coronary atherosclerotic obstructions is agerelated in both sexes Chen VY, et al. Circulation. 2011;124:2423-2432.
INFLAMMATION CORONARY STENOSIS
Thrombosis MYOCARDIAL ISCHEMIA
ENDOTHELIAL VASOSPASM DYSFUNCTION MICROVASCULAR DYSFUNCTION
Mechanisms contributing to myocardial ischemia in man: a preliminary list…
Myocardial ischaemia Myocardial ischemia‌ complex mechanism Vasospasm Thrombus Atherosclerosis
O2 Supply
O2 Demand
Afterload Heart rate Contractility Preload
Myocardial Ischaemia Ischaemia Left ventricular remodeling
Acute coronary syndrome
Myocardial chronic ischemia
Usual management: The “haemodynamic pipeline Approach” • Vasodilators
(Nitrates, Nicorandil) • Beta-blockers • Calcium channel blockers • Revascularization
Myocardial ischemia result in major disturbances of energy production
Anaerobic Fatty acid
glycolysis
oxidation
Uncoupling between glycolysis and glucose oxidation.
Cell acidosis
Increase in FA oxidation inhibits glucose oxidation.
Calcium overload
Increase need of ATP for homeostasis. Stanley WC, et al. Cardiovasc Res. 1997;34:25-33. Pilz S, et al. Clin Chem Lab Med. 2008;46:429-434.
Therapeutic perspectives for agents modulating cardiac energy metabolism
Heart Metab. 2008;38:5-14,
Significant improvement of ergometric parameters versus placebo Ns (Npt)
E (IC)
Trimetazidine
TED
170 (15744)
0.38 (0.23; 0.55)
Trimetazidine
T1
126 (13598)
0.46 (0.29; 0.64)
Trimetazidine
T0A
111 (11652)
0.45 (0.20; 0.70)
All anti-anginal agents All anti-anginal agents All anti-anginal agents
TED T1 T0A
158 (13791) 117 (12440) 105 (10905)
0.32 (0.26; 0.38) 0.47 (0.39; 0.56) 0.38 (0.29; 0.47)
Dihydropyridines Dihydropyridines Dihydropyridines
TED T1 T0A
170 (15744) 126 (13598) 111 (11652)
0.34 (0.27; 0.41) 0.52 (0.42; 0.62) 0.42 (0.32; 0.53)
Long-acting nitrates Long-acting nitrates Long-acting nitrates
TED T1 T0A
170 (15744) 126 (13598) 111 (11652)
0.30 (0.22; 0.38) 0.40 (0.28; 0.53) 0.31 (0.18; 0.44)
Nicorandil Nicorandil Nicorandil
TED T1 T0A
170 (15744) 126 (13598) 111 (11652)
0.32 (0.04; 0.60) 0.43 (0.10; 0.77) 0.75 (0.09; 0.81)
Ranolazine Ranolazine Ranolazine
TED T1 T0A
2 (966) 2 (966) 2 (966)
0.29 (0.09; 0.50) 0.33 (-0.03; 0.69) 0.31 (0.09; 0.53)
Ns (NPT): Number of studies (nb of patients) involved in the network E (IC): Estimate of the difference between treatment effects (corresponding credibility interval)
-0.1
0.0 0
0.1 -12
Favours placebo
0.2
0.3 -36
0.4
0.5 -60
0.6
0.7 0.8 seconds
Favours active comparators
Danchin N, et al. Eur Heart J. 2011;32 (Suppl. 1):572.
0.9
Optimizing energy metabolism with Trimetazidine MR: a key target in all stages of ischemic heart disease
Beadle G. and Frenneaux M. Heart 2010;96:824-830.
Guidelines
Metabolic antianginal drugs may be used in combination with conventional agents, as their primary effect is not through reduction in HR or BP, or as substitution therapy when conventional drugs are not tolerated
Role of HR in the pathophysiology of CAD Increasing heart rate Vascular damage Atherosclerosis
Increased O2 demand Decreased supply
Progression of atherosclerosis
Ischemia
Major CV events
Short term
Long term
Plaque rupture
Heart rate as a predictor of major cardiovascular events in stable CAD patients The TNT study (n=9580) Major cardiovascular events (%)
Major CV event: CAD death, nonfatal MI, resuscitated cardiac arrest, stroke Ho JE, et al. Am J Cardiol. 2010;105:905-911.
Inadequate control of heart rate in patients with stable angina The Euro Heart Survey; 2005 patients Patients (%) in different HR ranges according to HR-lowering treatment at baseline
35 CCBs
30
BBs
25 20 15 10 5 0 ≤62
63-70
Daly C et al. Postgrad Med J 2010;86:212-217.
71-76
77-82
≼83
Resting HR (bpm)
Ivabradine further reduces HR in patients already receiving β-blocker Heart rate (bpm) 68
67
66
66
66 64
Ivabradine 5 mg bid
Placebo + atenolol
62
Ivabradine + atenolol
60 60 (- 7 bpm) 58
Ivabradine 7.5 mg bid
58 (- 9 bpm)
56
Ivabradine 7.5 mg bid (90% of patients) or 5 mg bid (10%) 54 Baseline
Tardif JC, et al. Eur Heart J. 2009;30:540-548.
M2
M4
Combining ivabradine with beta-blocker provides additional anti-ischemic efficacy P<0.05
Workload on treadmill testing, METs
Ivabradine + bisoprolol Bisoprolol
P=0.004
Bisoprolol 5 mg
Amosova E. et al. Cardiovasc Drugs Ther 2011.
Bisoprolol 5 mg + Ivabradine (5-7.5 mg)
After 2 months
Baseline
After 2 months
Baseline
P=0.141
Bisoprolol 5 mg Bisoprolol 5 mg + Bisoprolol 5 mg
Effect of ivabradine on hospitalization for fatal/nonfatal MI Angina and HR >70 bpm (n = 712)
Angina (n = 1507) Event rate (%) 15
Event rate (%) 15
HR = 0.58 P=0.021
10
Placebo
42%
5
HR = 0.27 P=0.002
10
Placebo
5
73%
Ivabradine 0
Ivabradine
0 0
0.5
1 Years
1.5
Fox K, et al. Eur Heart J. 2009; 30:2337-2345.
2
0
0.5
1 Years
1.5
2
www.escardio.org/guidelines
www.escardio.org/guidelines
www.escardio.org/guidelines
COURAGE TRIAL
Boden WE et al. N Engl J Med 2007;356:1503-1516
COURAGE TRIAL Conclusion
â&#x20AC;˘ As an initial management strategy in patients with stable coronary artery disease, PCI did not reduce the risk of death, myocardial infarction, or other major cardiovascular events when added to optimal medical therapy
Boden WE et al. N Engl J Med 2007;356:1503-1516
fjp
Fractional Flow Reserve for the Determination of Hemodynamicall Significant Stenosis Fractional Flow Reserve > 0.80
Fractional Flow Reserve < 0.80
ESC Textbook of Cardiovascular Medicine, J.C. Camm, T.F. L端scher, P.W. Serruys eds., Oxford University Press 20092nd Edition,
fjp
fjp
FAME Study Conclusion â&#x20AC;˘ Routine measurement of FFR in patients with multivessel CAD who are undergoing PCI with drugeluting stents significantly reduces the rate of the composite end point of death, nonfatal myocardial infarction, and repeat revascularization at 1 year Tonino PAL et al. N Engl J Med 2009;360:213-224
fjp
FFR vs. Angiography for Guiding PCI in Patients with Multivessel CAD â&#x20AC;&#x201C; Economic Evaluation
Fearon W F et al. Circulation 2010;122:2545-2550
fjp
www.escardio.org/guidelines
64 yo male with angina clII and abnl Treadmill test
fjp
64 yo male with angor clII and abnl Treadmill test
fjp
Basal IVUS
â&#x20AC;˘Lipid lake in ulcerated plaque fjp
Fractional Flow Reserve
fjp
Angioplastia de lesão da DA com controlo anatómico e fisiológico
Angioplastia
• DES (Everolimus) 3,0 x 16 mm implantado a 14 atm.
fjp
Fractional Flow Reserve â&#x20AC;&#x201C; Post LAD PCI
fjp
COURAGE vs FAME
In the COURAGE study, optimal medical treatment only and PCI in addition to medical treatment were investigated in patients with multivessel disease and moderately severe coronary disease. In most patients, bare metal stents were used. The FAME study had broader inclusion criteria, including unstable patients and non–ST-segment elevation MI, and decreased left ventricular function, including patients who had undergone a previous PCI. fjp
Major Adverse Event Rate
Pijls, N. H. J. et al. J Am Coll Cardiol 2012;59:1045-1057
Conclusion Chronic ischemic heart disease is a significant clinical burden IHD may result from a number of mechanisms, including atherosclerotic obstructions, coronary vasomotor dysfunction, endothelial dysfunction, platelet dysfunction, etc. Addressing the individual consequences of ischemia is essential to ensure an optimal management of IHD
Speaker